Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma 149Lymphoma, Large B-Cell, Diffuse 114Lymphoma, Non-Hodgkin 110Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 81Hodgkin Disease 81Small Cell Lung Carcinoma 79Leukemia, Myeloid, Acute 73Burkitt Lymphoma 69Lymphoma, Follicular 67Lymphoma, Mantle-Cell 65Lung Neoplasms 60Lymphoma, Large-Cell, Immunoblastic 54Leukemia, Lymphocytic, Chronic, B-Cell 47Recurrence 40Multiple Myeloma 39Lymphoma, B-Cell, Marginal Zone 36Neuroblastoma 33Congenital Abnormalities 29Carcinoma, Non-Small-Cell Lung 28Lymphoma, B-Cell 25Myelodysplastic Syndromes 24Lymphoma, Large-Cell, Anaplastic 23Lymphoma, Extranodal NK-T-Cell 23Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Brain Neoplasms 22Sarcoma 21Ovarian Neoplasms 21Lymphoma, T-Cell, Peripheral 20Central Nervous System Neoplasms 20

Interventions

Dexamethasone 16Calcium Dobesilate 9Melphalan 6Lenalidomide 6Cyclophosphamide 5Bortezomib 5pomalidomide 3venetoclax 2daratumumab 2Thalidomide 2Doxycycline 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2selinexor 1pegfilgrastim 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1belantamab mafodotin 1auricularum 1Vinorelbine 1Technetium Tc 99m Pyrophosphate 1Technetium 1Tacrolimus 1Surveys and Questionnaires 1Interleukin-2 1In Situ Hybridization, Fluorescence 1In Situ Hybridization 1Hyaluronoglucosaminidase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Amyloidosis × Etoposide × Clear all
NCT01548573 2017-06-14

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

University of Iowa

Phase 2 Terminated
19 enrolled 7 charts
Plasma cell

Amyloidosis, Endocrine System Diseases, Multiple Myeloma, Paraproteinemias, Polyneuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡